

Kaynes Technologies

Estimate change	↓
TP change	↑
Rating change	↔

Bloomberg	KAYNES IN
Equity Shares (m)	67
M.Cap.(INRb)/(USD\$)	258.5 / 2.7
52-Week Range (INR)	7705 / 2995
1, 6, 12 Rel. Per (%)	16/9/-37
12M Avg Val (INR M)	6690

Financials & Valuations (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	36.3	51.9	71.9
EBITDA	5.7	8.4	11.9
Adj. PAT	3.7	5.1	8.4
EBITDA Margin (%)	15.8	16.1	16.5
Cons. Adj. EPS (INR)	54.6	75.5	125.5
EPS Gr. (%)	24.7	38.1	66.3
BV/Sh. (INR)	709.2	784.6	910.1

Ratios

Net D:E	0.0	-0.2	-0.3
RoE (%)	9.6	10.1	14.8
RoCE (%)	9.6	10.3	14.4

Valuations

P/E (x)	70	51	31
EV/EBITDA (x)	45	29	20

Shareholding pattern (%)

As on	Jun-26	Mar-26	Jun-25
Promoter	53.5	53.5	53.5
DII	11.8	15.1	22.4
FII	5.8	7.3	10.7
Others	28.9	24.1	13.4

Note: FII includes depository receipts

CMP: INR3,856 **TP: INR5,000 (+30%)** **Buy**

Core EMS business drives growth

Operating performance above our estimates

- Kaynes Technologies (KAYNES) reported a healthy operating performance in 1QFY27, with EBITDA growth of 31% YoY to INR1.5b (est. INR1.3b). This was largely fueled by strong growth in its core EMS business (+48% YoY), which more than offset the decline in smart-metering revenue (-12% YoY). Further, Automotive/Industrials/Aerospace/Medical/ IT/Railways grew 35%/31%/2.8x/2.8x/69%/81% YoY to INR2.5b/INR5.2b/INR189m/INR189m/INR568m/INR851m.
- Beyond core business, the company is targeting a combined revenue of INR4.5-5.0b from OSAT and PCB in FY27. Further, WC days were up by 41 days, driven by inventory build-up to secure critical components amid supply chain disruptions and long lead times.
- However, as inventory is consumed, supply conditions improve, and the company de-risks smart-metering receivables, working capital is expected to normalize. This should support stronger cash conversion and the company's target of turning cash-positive by the end of FY27.
- Factoring in the lower-than-estimated 1Q earnings due to higher depreciation and tax and lower other income, we cut our FY27/FY28 earnings estimates by 11%/5%, respectively. **We reiterate our BUY rating with a TP of INR5,000, based on 40x FY28E EPS.**

Broad-based growth across all verticals

- KAYNES' consolidated revenue grew 41% YoY to INR9.5b (est. INR8.6b) in 1QFY27; EBITDA grew 31% YoY to INR1.5b (est. INR1.3b). EBITDA margin dipped 120bp YoY to 15.6% (est. 15.5%) due to a contraction in gross margin (down 7pp YoY) and a rise in employee expenses (up 30bp YoY). These were partly offset by other expenses (-6pp YoY). Adj. PAT declined 24% YoY.
- Automotive/Industrials/Aerospace/Medical/ IT/Railways grew 35%/31%/2.8x/2.8x/69%/81% YoY to INR2.5b/INR5.2b/INR189m/INR189m/INR568m/INR851m YoY.
- Order inflows remained flat YoY at INR14.8b in 1Q, with the order book growing 20%/6% YoY/QoQ.
- Net working capital days rose to 163 in 1QFY27 from 122 in 1QFY26.

Key highlights from the management commentary

- **PCB:** Kaynes has planned INR3b capex in FY27 for PCB (INR3.2b capex in FY26), with commercial production and revenue expected from 3Q/4QFY27. Initial capacity has been fully sought by a large global customer, which has completed validation and provided a vendor code. PCB margins are expected to remain stable despite near-term input-cost pressures.

Research Analyst: **Sumant Kumar** (Sumant.Kumar@MotilalOswal.com) | **Yash Darak** (Yash.darak@MotilalOswal.com)

Research Analyst: **Nirvik Saini** (Nirvik.Saini@MotilalOswal.com) | **Swapnil Upadhyay** (Swapnil.Upadhyay@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **OSAT business:** Kaynes has planned INR3b capex in FY27 for OSAT (INR4.7b in FY26), with commercial revenue expected to commence from 3Q/4QFY27 and the project remaining on track despite minor delays from West Asia-related equipment and logistics disruptions. The company has received ~INR1.7b of government subsidy for OSAT, supporting project funding. Further, the strategic partnership with Mitsui provides access to the Japanese semiconductor market, while customer trials and validations are progressing.
- **Space tech:** Kaynes is developing its first prototype satellite, with launch targeted for mid-FY28, subject to regulatory testing and a confirmed launch date from ISRO. At ISRO's request, the company is entering titanium gas-bottle manufacturing for flight programs. Further, DRDO also has similar requirements for missile programs, providing a second anchor customer and expanding Kaynes' presence in the space and defense electronics ecosystem.

Valuation and view


- KAYNES reported a healthy operating performance in 1QFY27 with growth across all segments. With a robust order book as of Jun'26 (INR89b, up 20%), the company is likely to sustain strong revenue growth momentum going forward.
- Going forward, KAYNES' growth will be driven by continued scaling of its core EMS business, with growth across all verticals. OSAT and PCB are expected to emerge as key growth engines, with commercialization targeted from 3Q/4QFY27. The company's expansion into space and defense electronics should further diversify its growth profile.
- We estimate a revenue/EBITDA/adj. PAT CAGR of 41%/44%/52% over FY26-FY28. **Reiterate BUY with a TP of INR5,000 (premised on 40x FY28E EPS).**

Consolidated - Quarterly Earnings

Y/E March	(INR m)											
	FY26				FY27E				FY26	FY27	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			1QE	%
Gross Sales	6,735	9,062	8,040	12,426	9,460	12,234	12,865	17,336	36,264	51,895	8,620	10%
YoY Change (%)	33.6	58.4	21.6	26.2	40.5	35.0	60.0	39.5	33.2	43.1	28.0	
Total Expenditure	5,604	7,582	6,847	10,489	7,984	10,198	10,858	14,485	30,523	43,525	7,287	
EBITDA	1,130	1,480	1,193	1,937	1,476	2,036	2,007	2,851	5,741	8,369	1,334	11%
Margins (%)	16.8	16.3	14.8	15.6	15.6	16.6	15.6	16.4	15.8	16.1	15.5	
Depreciation	156	166	204	544	370	400	450	500	1,071	1,720	250	
Interest	284	228	249	409	371	325	275	250	1,169	1,221	350	
Other Income	271	431	448	419	144	200	550	554	1,568	1,448	450	
PBT before EO expense	961	1,517	1,189	1,403	879	1,511	1,832	2,655	5,069	6,876	1,184	
Extra-Ord expense	0	0	25	0	0	0	0	0	26	0	0	
PBT	961	1,517	1,163	1,402	879	1,511	1,832	2,655	5,043	6,876	1,184	
Tax	215	303	397	490	315	380	461	668	1,404	1,824	260	
Rate (%)	22.3	20.0	34.1	34.9	35.8	25.2	25.2	25.2	27.8	26.5	22.0	
Reported PAT	746	1,214	766	912	564	1,131	1,371	1,986	3,639	5,052	923	
Adj PAT	746	1,214	785	913	564	1,131	1,371	1,986	3,658	5,052	923	-39%
YoY Change (%)	46.9	101.7	18.2	-21.5	-24.4	-6.9	74.5	117.7	24.6	38.1	23.7	
Margins (%)	11.1	13.4	9.8	7.3	6.0	9.2	10.7	11.5	10.1	9.7	10.7	


Key Exhibits

Exhibit 1: Consolidated order book trend




Source: Company, MOFSL

Exhibit 2: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 3: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 4: Consolidated adj. PAT trend




Source: Company, MOFSL

Exhibit 5: Product-wise revenue mix




Source: Company, MOFSL

Exhibit 6: End-user industry-wise revenue mix



Source: Company, MOFSL

Exhibit 7: Key growth trends across end-user verticals



Source: MOFSL, Company



Highlights from the management commentary

Guidance

- The company expects to grow at ~2x the market growth rate.
- The company expects INR4.5–5b of combined revenue from OSAT and PCB.

Operations

- Escalation in West Asia has resulted in a slippage in the ramp-up schedule for PCB and OSAT.
- Overall revenue growth has been achieved despite a decline in the smart metering business, with strong growth in the core EMS business.
- The standalone EMS business has delivered strong growth.
- The delayed delivery of a government product, which was highlighted earlier, has now largely normalized, with ~30–40% of the pending business executed during the quarter, supporting growth across various segments.
- Other income has declined as income earned on QIP funds has reduced, while depreciation has increased due to higher capex.
- Standalone business revenue grew 53% YoY, from INR4.2b to INR6.4b. Overseas entities grew 327%, from INR240m to INR1b.
- The EMS market grew by 17%, while the company's EMS business grew by 48%, significantly outperforming the industry.
- The company reiterated its expectation of achieving ~2x market growth, irrespective of the underlying market growth rate.
- ETR remains elevated due to loss-making entities contributing to the consolidated business.
- Debt stood at ~INR8b.

Component price inflation

- MCUs and power devices: Prices have increased by 15–85%, reflecting tight semiconductor capacity and stronger demand for power-management components.
- DRAM and NAND: Prices have risen by 40–105%, driven by strong AI/data-center demand and the reallocation of memory capacity toward server applications.
- MLCCs and tantalum capacitors: Prices have increased by 15–60%, particularly across high-end and automotive-grade products.
- Chip resistors: Prices have risen by 15–25%, amid tighter supply and higher input costs.
- Diodes and MOSFETs: Prices are up 10–20%, with automotive and SiC products witnessing relatively higher supply constraints.
- Connectors: Prices have increased by 5–30%, reflecting higher demand across automotive, EV and AI-server applications.
- Overall, the combination of geopolitical disruptions, AI-led capacity crowd-out, elevated energy/input costs and precautionary inventory building is creating a tighter component market, with lead times extending and procurement costs rising across key electronics categories.
- Component availability has become challenging, with supply conditions resembling the tightness witnessed during the COVID period.

- The company proactively increased inventory to ensure uninterrupted availability of raw materials and components.
- Component availability remains a key constraint, while component prices have increased by ~10–12%

Working capital and cash flow

- The increase in inventory of ~INR1.5b was a strategic decision taken in February, considering the global market situation and supply-chain volatility.
- The higher inventory enabled the company to maintain strong growth, with overall growth exceeding 40% and EMS growth at ~48%.
- Inventory increased by INR1.6b.
- Receivables increased by ~INR900m.
- Negative cash flow stood at ~INR2.5b, compared with ~INR3b last year.
- Total receivables, including current and non-current assets, increased from INR 17.65b to INR19.25b during the quarter.
- EMS receivables remained broadly stable, increasing from INR6b to INR6.1b, indicating that collections were largely completed, including GST-related amounts.
- Receivables in the metering business increased from INR 11b to INR 13b, reflecting the weaker topline in the segment.

OSAT

- Capex of INR4.7b has been incurred/planned for the OSAT and semiconductor business.
- Received INR1.7b of government subsidy in July.
- Commercial revenue booking is expected to begin from 3Q/4Q.
- Trials and validation processes are nearing completion.

PCB

- Planned capex of INR3b.
- PCB has entered a phase of global supply shortage, with suppliers increasingly demanding advance payments and lead times of 6–8 months even for order booking.
- The company's timing of entry into PCB is therefore favorable, with commercial production expected to commence from the next quarter.
- Commercial revenue booking is expected from 3Q/4Q.
- The entire initial capacity has been sought by a large global customer, which has approved the company and provided the vendor quote.
- PCB margins have remained stable, with the business performing well despite the challenging environment

Space tech

- Satellite development: Kaynes' first prototype satellite is currently under development, with the company targeting launch by mid-FY28, subject to completion of regulatory testing.
- ISRO: The company is awaiting a confirmed launch date from ISRO, with the satellite expected to be launched aboard either on a Polar Satellite Launch Vehicle (PSLV) or on a Geosynchronous Satellite Launch Vehicle (GSLV).

Management highlighted that the initiative is aimed at establishing Kaynes' capabilities in the emerging satellite electronics segment and creating opportunities for broader participation in India's space ecosystem.

- DRDO: At the request of ISRO, Kaynes' subsidiaries Creo Precision and Kaynes Technology's aerospace subsidiary are entering titanium gas-bottle manufacturing to support ISRO's flight programs.
- Defense opportunity: DRDO has a similar requirement for titanium gas bottles across several missile programs, providing Kaynes with a second anchor customer in the space/defense segment from the outset.

Capex

- Planned capex for FY27 includes INR3b for OSAT, INR3b for PCB and INR2.5b for EMS.
- Capex incurred during 1Q stood at ~INR1.8b.
- Funding is not a constraint for the planned capex program.
- Government subsidies are also expected to support the company's capex requirements.

Valuation and view

- KAYNES reported a healthy operating performance in 1QFY27 with growth across all segments. With a robust order book as of Jun'26 (INR89b, up 20%), the company is likely to sustain strong revenue growth momentum going forward.
- Going forward, KAYNES' growth will be driven by continued scaling of its core EMS business, with growth across all verticals. OSAT and PCB are expected to emerge as key growth engines, with commercialization targeted from 3Q/4QFY27. The company's expansion into space and defense electronics should further diversify its growth profile.
- We estimate a revenue/EBITDA/adj. PAT CAGR of 41%/44%/52% over FY26-FY28. **Reiterate BUY with a TP of INR5,000 (premised on 40x FY28E EPS).**

Exhibit 8: Changes to our estimates

Earnings change (INR m)	Old		New		Change	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Revenue	51,055	72,753	51,895	71,883	2%	-1%
EBITDA	8,162	11,822	8,369	11,881	3%	0%
Adj. PAT	5,686	8,835	5,052	8,401	-11%	-5%
EPS	85	132	75	125	-11%	-5%

Financials and valuations

Consolidated - Income Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	3,682	4,206	7,062	11,261	18,046	27,218	36,264	51,895	71,883
Change (%)	1.1	14.2	67.9	59.4	60.3	50.8	33.2	43.1	38.5
RM Cost	2,417	2,861	4,894	7,801	13,299	18,997	23,719	34,722	46,005
Employees Cost	424	459	602	771	1,028	1,781	3,136	3,751	5,196
Other Expenses	428	477	629	1,006	1,178	2,333	3,669	5,052	8,801
Total Expenditure	3,269	3,797	6,126	9,578	15,505	23,111	30,523	43,525	60,002
% of Sales	88.8	90.3	86.7	85.1	85.9	84.9	84.2	83.9	83.5
EBITDA	413	409	937	1,683	2,542	4,107	5,741	8,369	11,881
Margin (%)	11.2	9.7	13.3	14.9	14.1	15.1	15.8	16.1	16.5
Depreciation	84	101	132	187	251	447	1,071	1,720	2,303
EBIT	330	308	805	1,496	2,290	3,660	4,670	6,649	9,577
Int. and Finance Charges	236	240	256	349	533	1,013	1,169	1,221	800
Other Income	19	40	41	114	559	1,070	1,568	1,448	1,994
PBT bef. EO Exp.	113	109	590	1,260	2,317	3,716	5,069	6,876	10,771
EO Items	0	0	0	0	0	0	26	0	0
PBT after EO Exp.	113	109	590	1,260	2,317	3,716	5,043	6,876	10,771
Total Tax	19	11	174	308	483	782	1,404	1,824	2,370
Tax Rate (%)	17.1	10.5	29.4	24.5	20.8	21.0	27.8	26.5	22.0
Minority Interest	0	0	0	0	0	0	0	0	0
Reported PAT	94	97	417	952	1,834	2,934	3,639	5,052	8,401
Adjusted PAT	94	97	417	952	1,834	2,934	3,658	5,052	8,401
Change (%)	-3.8	4.0	328.2	128.4	92.7	60.0	24.7	38.1	66.3
Margin (%)	2.5	2.3	5.9	8.5	10.2	10.8	10.1	9.7	11.7

Consolidated - Balance Sheet

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	68	68	462	581	639	641	670	670	670
Preference Capital	0	11	4	0	0	0	0	0	0
Total Reserves	959	1,308	1,560	9,009	24,230	27,762	46,813	51,866	60,267
Net Worth	1,027	1,387	2,026	9,590	24,869	28,403	47,483	52,535	60,936
Minority Interest	6	9	11	13	16	40	141	141	141
Total Loans	1,643	1,526	1,779	1,359	3,061	8,755	8,749	6,749	4,749
Deferred Tax Liabilities	79	52	68	77	102	130	185	185	185
Capital Employed	2,755	2,974	3,884	11,039	28,047	37,327	56,559	59,611	66,012
Gross Block	930	1,181	1,544	1,925	3,831	7,875	17,489	26,948	34,474
Less: Accum. Deprn.	382	483	615	802	1,054	1,501	2,572	4,292	6,595
Net Fixed Assets	547	698	929	1,123	2,777	6,374	14,917	22,656	27,879
Goodwill on Consolidation	23	23	23	23	152	141	161	161	161
Capital WIP	119	126	83	293	1,051	3,002	3,724	720	894
Total Investments	16	17	15	33	1,318	1,324	2,571	2,571	2,571
Current Investments	0	0	0	0	0	0	0	0	0
Curr. Assets, Loans&Adv.	3,075	3,330	5,173	12,715	27,354	35,571	47,568	59,637	70,574
Inventory	1,511	1,639	2,264	4,132	5,483	8,144	11,032	14,745	15,755
Account Receivables	937	1,218	1,977	2,271	3,556	5,746	15,276	14,929	20,679
Cash and Bank Balance	123	143	216	4,860	15,256	10,563	7,986	18,027	24,795
Loans and Advances	504	331	716	1,453	3,060	11,118	13,274	11,936	9,345
Curr. Liability & Prov.	1,027	1,219	2,340	3,148	4,605	9,085	12,382	26,133	36,066
Account Payables	921	954	1,641	2,229	3,610	6,829	8,508	11,226	14,874
Other Current Liabilities	76	226	648	857	920	2,130	3,696	14,648	20,833
Provisions	30	39	52	62	74	126	178	259	359
Net Current Assets	2,048	2,110	2,833	9,567	22,750	26,486	35,186	33,503	34,508
Misc Expenditure	0	0	0	0	0	0	0	0	0
Appl. of Funds	2,755	2,974	3,884	11,039	28,047	37,327	56,559	59,611	66,012

Financials and valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)									
EPS	1.4	1.5	6.2	14.2	27.4	43.8	54.6	75.5	125.5
Cash EPS	2.6	3.0	8.2	17.0	31.1	50.5	70.6	101.1	159.9
BV/Share	15.3	20.7	30.3	143.2	371.4	424.2	709.2	784.6	910.1
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Valuation (x)									
P/E	2,755.6	2,648.6	618.6	270.8	140.6	87.9	70.5	51.0	30.7
Cash P/E	1,453.6	1,301.3	470.1	226.3	123.6	76.2	54.5	38.1	24.1
P/BV	251.0	185.9	127.2	26.9	10.4	9.1	5.4	4.9	4.2
EV/Sales	7.5	6.6	25.4	19.6	13.0	9.0	7.1	4.8	3.3
EV/EBITDA	67.0	67.4	191.4	130.9	92.0	59.6	45.1	29.5	20.0
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	20.6	4.0	-4.6	-17.2	-32.7	-160.9	-274.9	176.4	113.1
Return Ratios (%)									
RoE	9.1	8.1	24.4	16.4	10.6	11.0	9.6	10.1	14.8
RoCE	10.8	11.2	17.8	16.5	11.6	11.5	9.6	10.3	14.4
RoIC	10.9	10.7	18.2	24.0	22.3	17.6	10.4	12.1	19.6
Working Capital Ratios									
Fixed Asset Turnover (x)	4.0	3.6	4.6	5.9	4.7	3.5	2.1	1.9	2.1
Asset Turnover (x)	1.0	1.0	1.1	0.8	0.6	0.6	0.5	0.6	0.7
Inventory (Days)	205	201	146	150	132	131	148	155	125
Debtor (Days)	106	93	83	69	59	62	106	105	105
Creditor (Days)	136	120	97	91	80	100	118	118	118
Leverage Ratio (x)									
Current Ratio	3.0	2.7	2.2	4.0	5.9	3.9	3.8	2.3	2.0
Interest Cover Ratio	1.4	1.3	3.1	4.3	4.3	3.6	4.0	5	12.0
Net Debt/Equity	1.5	1.0	0.8	-0.4	-0.5	-0.1	0.0	-0.2	-0.3

Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	113	109	590	1,260	2,317	3,716	5,043	6,876	10,771
Depreciation	84	101	132	187	251	447	1,071	1,720	2,303
Interest & Finance Charges	228	233	-11	-100	-27	1,013	1,140	-227	-1,194
Direct Taxes Paid	-19	-28	-22	-503	-483	-644	-1,399	-1,824	-2,370
(Inc)/Dec in WC	44	-137	-743	-1,629	-1,358	-4,522	-11,322	11,724	5,764
CF from Operations	451	277	-53	-784	701	10	-5,467	18,269	15,275
Others	2	0	265	365	0	-834	-537	0	0
CF from Operating incl EO	452	277	211	-419	701	-823	-6,004	18,269	15,275
(Inc)/Dec in FA	-312	-250	-422	-581	-2,792	-9,487	-12,403	-6,455	-7,700
Free Cash Flow	140	27	-211	-1,001	-2,091	-10,311	-18,407	11,814	7,575
(Pur)/Sale of Investments	205	2	-33	0	0	4,984	0	0	0
Others	8	7	11	-4,352	-12,261	957	3,231	1,448	1,994
CF from Investments	-99	-241	-445	-4,933	-15,052	-3,547	-9,172	-5,007	-5,706
Issue of Shares	0	270	228	6,600	13,436	2	16,016	0	0
Inc/(Dec) in Debt	-118	-44	301	-336	1,702	5,694	-1,145	-2,000	-2,000
Interest Paid	-236	-240	-256	-349	-533	-1,013	926	-1,221	-800
Dividend Paid	0	0	0	0	0	0	0	0	0
Others	0	-6	0	-371	-320	-33	0	0	0
CF from Fin. Activity	-354	-19	272	5,543	14,285	4,650	15,796	-3,221	-2,800
Inc/Dec of Cash	-1	17	38	191	-67	280	620	10,041	6,768
Opening Balance	8	126	143	216	4,860	15,255	10,563	7,986	18,027
Other cash & cash equivalent	115	0	35	4,453	10,462	-4,972	-3,197	0	0
Closing Balance	123	143	216	4,860	15,255	10,563	7,986	18,027	24,795

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online-reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:


Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.

MarketsZon

FINANCIAL NEWS PAPER, MAGAZINE, RESEARCH REPORTS, COURSE'S, BOOKS, IPO, INVESTMENT REPORTS etc.....



CLICK AND JOIN



ALL FINANCIAL NEWS PAPER'S & MAGAZINE AVAILABLE